drugset / Trial / NCT00753324

Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia

NCT00753324

RandomizedParallel-groupOpen-labelPrevention

Summary

The investigators will enroll a cohort of HIV-infected pregnant women accessing PMTCT services, to better understand the incremental benefits (e.g. reduction in HIV transmission, improvements in HIV-free survival) and risks (e.g. drug toxicities) of the routine HAART strategy, in comparison to HIV-infected pregnant women accessing the Zambian Standard of Care services. The investigators will test the hypothesis that routine use of HAART produces significant reductions in HIV transmission rates, with only minimal side effects.

Timeline

Start
2009-05
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamivudine Other / unclassified
Subject Lopinavir Other / unclassified
Subject Nevirapine Small molecule
Subject Ritonavir Other / unclassified
Subject Stavudine Other / unclassified
Subject Zidovudine Small molecule